Nelson R&D/Lilly Azone agreements
Nelson has reached two agreements with Lilly Internatl. covering the development of a cream formulation and a transdermal delivery patch for the overseas marketing of an unnamed compound. "The drug under development is already widely accepted as an oral product with 1983 worldwide sales of approximately $330 mil." and has been marketed worldwide for "more than a decade," Nelson said. The Irvine, Calif.-based research firm indicated that the same compound in Nelson delivery systems is being developed for another firm for domestic marketing.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.